StewartAKRajkumarSVDimopoulosMA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152. doi:10.1056/NEJMoa1411321
2.
DimopoulosMAMoreauPPalumboA, et al. Carfilzomib, and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27-38. doi:10.1016/S1470-2045(15)00464-7
3.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:org/10.1038/clpt.1981.154
4.
TalamoGSivikJPandeyMK, et al. Bortezomib-induced acute pancreatitis: case report and review of the literature. J Oncol Pharm Pract. 2016;22:332-334. doi:10.1177/1078155214563813
5.
SteinerREOrlowskiRZLeeHC, et al. Acute pancreatitis associated with ixazomib in a multiple myeloma patient. Acta Haematol. 2018;139:67-70. doi:10.1159/000484655
